178 related articles for article (PubMed ID: 24621807)
1. Impact of telmisartan on cardiovascular outcome in hypertensive patients at high risk: a Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease subanalysis.
Foulquier S; Böhm M; Schmieder R; Sleight P; Teo K; Yusuf S; Schumacher H; Unger T
J Hypertens; 2014 Jun; 32(6):1334-41. PubMed ID: 24621807
[TBL] [Abstract][Full Text] [Related]
2. Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease.
Verdecchia P; Sleight P; Mancia G; Fagard R; Trimarco B; Schmieder RE; Kim JH; Jennings G; Jansky P; Chen JH; Liu L; Gao P; Probstfield J; Teo K; Yusuf S;
Circulation; 2009 Oct; 120(14):1380-9. PubMed ID: 19770395
[TBL] [Abstract][Full Text] [Related]
3. Impact of sex on cardiovascular outcome in patients at high cardiovascular risk: analysis of the Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects With Cardiovascular Disease (TRANSCEND) and the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET).
Kappert K; Böhm M; Schmieder R; Schumacher H; Teo K; Yusuf S; Sleight P; Unger T;
Circulation; 2012 Aug; 126(8):934-41. PubMed ID: 22829023
[TBL] [Abstract][Full Text] [Related]
4. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial.
; Yusuf S; Teo K; Anderson C; Pogue J; Dyal L; Copland I; Schumacher H; Dagenais G; Sleight P
Lancet; 2008 Sep; 372(9644):1174-83. PubMed ID: 18757085
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies.
Tobe SW; Clase CM; Gao P; McQueen M; Grosshennig A; Wang X; Teo KK; Yusuf S; Mann JF;
Circulation; 2011 Mar; 123(10):1098-107. PubMed ID: 21357827
[TBL] [Abstract][Full Text] [Related]
6. Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease studies.
Verdecchia P; Dagenais G; Healey J; Gao P; Dans AL; Chazova I; Binbrek AS; Iacobellis G; Ferreira R; Holwerda N; Karatzas N; Keltai M; Mancia G; Sleight P; Teo K; Yusuf S;
J Hypertens; 2012 May; 30(5):1004-14. PubMed ID: 22495138
[TBL] [Abstract][Full Text] [Related]
7. Effect of telmisartan on QT interval variability and autonomic control in hypertensive patients with left ventricular hypertrophy.
Galetta F; Franzoni F; Fallahi P; Tocchini L; Graci F; Carpi A; Antonelli A; Santoro G
Biomed Pharmacother; 2010 Oct; 64(8):516-20. PubMed ID: 20044234
[TBL] [Abstract][Full Text] [Related]
8. Are ACE-inhibitors or ARB's still needed for cardiovascular prevention in high risk patients? Insights from profess and transcend.
Van Mieghem W; Billiouw JM; Brohet C; Dupont AG; Gazagnes MD; Heller F; Krzesinski JM; Missault L; Persu A; Piérard L; Rottiers R; Vanhooren G; Vervaet P; Herman AG
Acta Clin Belg; 2010; 65(2):107-14. PubMed ID: 20491360
[TBL] [Abstract][Full Text] [Related]
9. The ONTARGET/TRANSCEND Trial Programme: baseline data.
Sleight P
Acta Diabetol; 2005 Apr; 42 Suppl 1():S50-6. PubMed ID: 15868120
[TBL] [Abstract][Full Text] [Related]
10. Microalbuminuria and hypertension in HIV-infected patients: a preliminary study of telmisartan.
Ucciferri C; Falasca K; Mancino P; Di Iorio A; Vecchiet J
Eur Rev Med Pharmacol Sci; 2012 Apr; 16(4):491-8. PubMed ID: 22696876
[TBL] [Abstract][Full Text] [Related]
11. The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.
Heerspink HJ; Gao P; de Zeeuw D; Clase C; Dagenais GR; Sleight P; Lonn E; Teo KT; Yusuf S; Mann JF
Eur J Prev Cardiol; 2014 Mar; 21(3):299-309. PubMed ID: 24191305
[TBL] [Abstract][Full Text] [Related]
12. Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) Trials.
Böhm M; Baumhäkel M; Teo K; Sleight P; Probstfield J; Gao P; Mann JF; Diaz R; Dagenais GR; Jennings GL; Liu L; Jansky P; Yusuf S;
Circulation; 2010 Mar; 121(12):1439-46. PubMed ID: 20231536
[TBL] [Abstract][Full Text] [Related]
13. Telmisartan improves vascular function independently of metabolic and antihypertensive effects in hypertensive subjects with impaired glucose tolerance.
Perl S; Schmölzer I; Sourij H; Pressl H; Eder M; Zweiker R; Wascher TC
Int J Cardiol; 2010 Mar; 139(3):289-96. PubMed ID: 19118910
[TBL] [Abstract][Full Text] [Related]
14. Main results and clinical interpretations from the TRANSCEND study.
de la Sierra A
J Hypertens Suppl; 2009 Jun; 27(2):S22-5. PubMed ID: 19491618
[TBL] [Abstract][Full Text] [Related]
15. Reduction (TELMAR) as assessed by magnetic resonance imaging in patients with mild-to-moderate hypertension--a prospective, randomised, double-blind comparison of telmisartan with metoprolol over a period of six months rationale and study design.
Friedrich MG; Dahlöf B; Sechtem U; Unger T; Knecht M; Dietz R;
J Renin Angiotensin Aldosterone Syst; 2003 Dec; 4(4):234-43. PubMed ID: 14689371
[TBL] [Abstract][Full Text] [Related]
16. Serial evaluation of electrocardiographic left ventricular hypertrophy for prediction of risk in hypertensive patients.
Okin PM
J Electrocardiol; 2009; 42(6):584-8. PubMed ID: 19631946
[TBL] [Abstract][Full Text] [Related]
17. Are the effects of telmisartan more marked in hypertensive patients?
Chalmers J
J Hypertens; 2014 Jun; 32(6):1201-2. PubMed ID: 24781511
[No Abstract] [Full Text] [Related]
18. Telmisartan to prevent recurrent stroke and cardiovascular events.
Yusuf S; Diener HC; Sacco RL; Cotton D; Ounpuu S; Lawton WA; Palesch Y; Martin RH; Albers GW; Bath P; Bornstein N; Chan BP; Chen ST; Cunha L; Dahlöf B; De Keyser J; Donnan GA; Estol C; Gorelick P; Gu V; Hermansson K; Hilbrich L; Kaste M; Lu C; Machnig T; Pais P; Roberts R; Skvortsova V; Teal P; Toni D; VanderMaelen C; Voigt T; Weber M; Yoon BW;
N Engl J Med; 2008 Sep; 359(12):1225-37. PubMed ID: 18753639
[TBL] [Abstract][Full Text] [Related]
19. Impact of lower achieved blood pressure on outcomes in hypertensive patients.
Okin PM; Hille DA; Kjeldsen SE; Dahlöf B; Devereux RB
J Hypertens; 2012 Apr; 30(4):802-10; discussion 810. PubMed ID: 22343536
[TBL] [Abstract][Full Text] [Related]
20. Telmisartan shown to reduce cardiovascular death, myocardial infarction and stroke in ACE-intolerant high-risk patients.
Cardiovasc J Afr; 2008; 19(5):275. PubMed ID: 18997991
[No Abstract] [Full Text] [Related]
[Next] [New Search]
